Sofosbuvir & Velpatasvir



What is Velpanat and what is it used for? Velpanat (generic Epclusa) is a generic antiviral drug produced by Natco that is used to Treat Chronic hepatitis C in adults. Velpanat contains active substances and velpatasvir sofosbuvir. How is Velpanat used? Velpanat can only be obtained with a prescription and treatment should be initiated and supervised by a physician experienced in the management of patients with chronic hepatitis C.

Velpanat is available as tablets containing 400 mg of sofosbuvir and 100 mg of velpatasvir. Hepatitis C virus exists in several varieties (genotypes), and Velpanat can be used to treat hepatitis C caused by all genotypes of the virus. The recommended dose is one tablet taken once a day for 12 weeks. In patients with decompensated liver disease (when the liver is no longer functioning properly), Velpanat is taken together with another medicine, called ribavirin.

Addition of ribavirin to Velpanat treatment may also be considered in patients with compensated liver cirrhosis (liver sclerosis but with proper functioning) and who are infected with hepatitis C virus genotype 3, which is harder to treat. How does Velpanat work? Velpanat active substances, sofosbuvir and velpatasvirul, blocking two proteins essential for replication of hepatitis C virus sofosbuvir block the action of an enzyme called "NS5B RNA-dependent RNA polymerase" and velpatasvirul targets a protein called "NS5A".

Blocking these proteins, Velpanat stops multiplication of hepatitis C virus infection of new cells. What is the risk associated with Velpanat? Velpanat is contraindicated in combination with the following medicines, as they may reduce the levels of sofosbuvir and velpatasvir in the blood, and can therefore reduce the efficacy of Velpanat: - rifampicin, rifabutin (antibiotics); - carbamazepine, phenobarbital, phenytoin (medicines to treat epilepsy); - St John's wort (herbal tea used to treat depression and anxiety). For the full list of side effects or restrictions with Velpanat, read the prospectus. The product summary and package leaflet included recommendations and precautions for the safe and effective use of Velpanat, to be followed by healthcare professionals and patients.

Brand name: Velpanat

Active Ingeridents: Sofosbuvir-400Mg-Velpatasvir-100Mg

Company Name: Natco

Package: 28 tabs/bottle

Strength : 400 MG & 100 MG

Sofosbuvir Mechanism of action:

Sofosbuvir Plus Velpatasvir is an oral fixed-dose combination of sofosbuvir, a nucleotide analog NS5B polymerase inhibitor and velapatasvir, an NS5A replication complex inhibitor. Sofosbuvir is approved for the treatment of genotype 1, 2, 3 and 4 HCV infection with different regimens and durations dependent on the HCV genotype. Velpatasvir (formerly GS-5816) is a novel NS5A inhibitor that has potent invitro anti-HCV activity across all genotypes at the picomolar level. The combination of sofosbuvir plus velpatasvir is the first once-daily single-tablet regimen with pangenotypic activity.

Dosage and Administration:

Sofosbuvir With Velpatasvir is available as a coformulated, once-daily single-pill combination of sofosbuvir 400 mg plus velpatasvir 100 mg. The recommended dose is one tablet once daily, taken with or without food.

  • Renal Impairment: For patients with mild to moderate renal impairment, no dosage adjustment of sofosbuvir-velpatasvir is recommended. There are insufficient data regarding the safety and efficacy of sofosbuvir-velpatasvir in patients with severe renal impairment (eGFR less than 30 ml/min/1.73m2) or end-stage renal disease requiring hemodialysis. Accordingly, no dosage recommendation has been given for patients with severe renal impairment or end-stage renal disease requiring dialysis.
  • Hepatic Impairment: For patients with mild, moderate, or severe hepatic impairment (Child-Pugh Class A, B, or C), no dosage adjustment for sofosbuvir plus velpatasvir is recommended. For patients with decompensated cirrhosis who are receiving sofosbuvir-velpatasvir and ribavirin, clinical and laboratory monitoring is recommended.


Sofosbuvir With Velpatasvir room temperature away from moisture and heat.


Sofosbuvir plus Velpatasvir is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Sofosbuvir Side effects:

The most common Side effects (≥10%, all grades) with Sofosbuvir plus Velpatasvir were headache and fatigue; and when used with Ribavirin in decompensated cirrhotics were fatigue, anemia, nausea, headache, insomnia, and diarrhea.


  • Risk of Serious Symptomatic Bradycardia When Sofosbuvir Is Coadministered with Amiodarone and Another HCV Direct Acting Antiviral: Amiodarone is not recommended for use with Sofosbuvir plus Velpatasvir due to the risk of symptomatic bradycardia, particularly in patients also taking beta blockers or with underlying cardiac comorbidities and/or with advanced liver disease. In patients without alternative, viable treatment options, cardiac monitoring is recommended. Patients should seek immediate medical evaluation if they develop signs or symptoms of bradycardia.
  • Risk of Reduced Therapeutic Effect Due to Concomitant Use of Sofosbuvir With Velpatasvir with P-gp Inducers and/or Moderate to Potent Inducers of CYP2B6, CYP2C8 or CYP3A4: Rifampin, St. John’s wort, and carbamazepine are not recommended for use with Sofosbuvir plus Velpatasvir as they may significantly decrease sofosbuvir and/or velpatasvir plasma concentrations.